<DOC>
	<DOCNO>NCT02605954</DOCNO>
	<brief_summary>This study evaluate efficacy switch elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( E/C/F/TAF ) fixed-dose combination ( FDC ) relative continue baseline regimen consist abacavir/lamivudine ( ABC/3TC ) plus 3rd antiretroviral agent maintain HIV-1 virologic suppression .</brief_summary>
	<brief_title>Safety Efficacy Switching From Regimens ABC/3TC + 3rd Agent E/C/F/TAF Fixed-Dose Combination ( FDC ) Virologically-Suppressed HIV 1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>HIVinfected adult subject meet follow criterion give option participate study : Currently receive ABC/3TC plus third antiretroviral ( ARV ) agent ≥ 6 consecutive month precede screen visit . For subject 3 ART regimen , regimen history must provide Sponsor approval . Allowed third antiretroviral agent include LPV/r , ATV+RTV , ATV+COBI ( ATV/COBI FDC ) , DRV+RTV , DRV + COBI ( DRV/COBI FDC ) FPV + RTV , SQV + RTV , ATV ( booster ) , EFV , RPV , NVP , ETR , RAL DTG Documented plasma HIV1 RNA level &lt; 50 copies/mL ≥ 6 month precede screen visit ( measure least twice use assay ) . In precede 6 month prior screen , one episode `` blip '' ( HIV1 RNA &gt; 50 &lt; 400 copies/mL ) acceptable , HIV1 RNA &lt; 50 copies/mL immediately `` blip '' . Plasma HIV1 RNA &lt; 50 copies/mL screen visit Individuals evidence previous virologic failure PI+RTV integrase strand transfer inhibitorbased regimen ( without resistance either class ARV ) . All document historical plasma genotype ( ) must show resistance tenofovir disoproxil fumarate ( TDF ) emtricitabine ( FTC ) , include , limited presence reverse transcriptase resistance mutant K65R , K70E , M184V/I , thymidine analog associate mutation ( TAMs ) ( TAMs : M41L , D67N , K70R , L210W , T215Y/F , K219Q/E/N/R ) . If historical genotype available subject 3 ART regimen , subject proviral genotype analysis prior Day 1 confirm absence archive resistance TDF FTC . Adequate renal function define estimate glomerular filtration rate ≥ 30 mL/min calculate CockcroftGault ( eGFRCG ) Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV 1 Infection</keyword>
	<keyword>HIV</keyword>
	<keyword>Virologically-Suppressed</keyword>
	<keyword>Antiretroviral agent</keyword>
</DOC>